^
Association details:
| Biomarker: | CD79B mutation + TNFAIP3 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | KT-413 (IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2088 Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models
Published date:
11/04/2020
Excerpt:
Importantly, activity was observed in models with a variety of co-mutations that activate the NFkB pathway, including alterations in, CD79B and TNFAIP3…
